MKI67 and neoplasm: Probably, these neoplasms, which present a moderate differentiation and a high Ki-67 index, may benefit from combined RLT and chemotherapy (i.e., capecitabine and/or temozolomide), with the latter working both as radiosensitizer agent and offering a therapeutic effect on [18F]FDG-positive lesions [115].